Citation

Richter D, James JC, Ebert A, Katsanos AH, Mazul-Wach L, Ruland Q, Gold R, Juckel G, Krogias C. J. Clin. Med. 2021; 10(24).

Copyright

(Copyright © 2021, MDPI: Multidisciplinary Digital Publishing Institute)

DOI

10.3390/jcm10245912

PMID

unavailable

Abstract

There are controversial data on the efficacy and safety profile of selective serotonin reuptake inhibitors (SSRIs) to prevent post-stroke depression (PSD). We performed a systematic search in MEDLINE and SCOPUS databases to identify randomized-controlled trials questioning the use of early SSRI therapy in the post-stroke population and its effect on PSD incidence. We included 6 studies with 6560 participants. We extracted the data on PSD occurrence in association with the treatment arm (SSRI versus placebo), as reported by each study. For safety analysis, we extracted the information on adverse events. A random-effects model was used to calculate the pooled relative risk estimates. Early SSRI therapy was associated with a significant reduction of PSD occurrence compared to placebo (10.4% versus 13.8%; relative risk: 0.75 [95% CI, 0.66-0.86]; absolute risk reduction: 3.4%). SSRI therapy increases the risk of bone fracture (RR 2.28 [95% CI, 1.58-3.30]) and nausea (RR 2.05 [95% CI, 1.10-3.82]) in the post-stroke population. Considering the risk-benefit ratio of early SSRI therapy in the post-stroke population, future research should identify high-risk patients for PSD to improve the risk-benefit consideration of this therapy for use in clinical practice. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

Language: en

Keywords

adult; human; suicide; systematic review; female; male; aged; incidence; Post-stroke depression; early intervention; death; fracture; fluoxetine; sertraline; Stroke; middle aged; bleeding; falling; psychopharmacotherapy; drug safety; placebo; cerebrovascular accident; follow up; drug efficacy; meta analysis; risk benefit analysis; nausea; side effect; escitalopram; brain hemorrhage; risk reduction; DSM-IV; Montgomery Asberg Depression Rating Scale; Article; functional status; acute coronary syndrome; data extraction; randomized controlled trial (topic); Medline; Serotonin reuptake inhibitor; Patient Health Questionnaire 9; post-stroke depression; Scopus; Hospital Anxiety and Depression Scale-Depression; data completeness; data consistency; ischemic stroke